The Role of Nivolumab PK Monitoring
Cancer immunotherapy has transformed treatment outcomes, with Nivolumab (OPDIVO®) leading the charge as a powerful immune checkpoint inhibitor. However, optimizing its dosage remains a challenge due to variability in patient responses. This is where pharmacokinetic (PK) monitoring plays a crucial role.
Introducing the DeQuanto® Nivolumab PK ELISA Kit – a cutting-edge tool designed for the accurate quantification of Nivolumab in human plasma and serum. Developed by Denovo Biolabs, this kit empowers clinicians and researchers to:
- Monitor drug levels for optimal therapeutic efficacy
- Minimize toxicity risks through precise dose adjustments
- Support personalized cancer treatment strategies
Why Monitor Nivolumab Levels?
Nivolumab’s effectiveness depends on maintaining optimal drug concentrations. Too little can lead to suboptimal tumour control, while excessive levels may increase toxicity risks.
PK monitoring helps:
- Confirm therapeutic drug levels
- Identify patients with unusual drug metabolism
- Guide dose adjustments in special populations
- Support research into exposure-response relationships
How the DeQuanto® Nivolumab PK ELISA Kit Works
This sandwich ELISA-based kit uses recombinant PD-1 protein to specifically capture Nivolumab. Key features include:
- High Sensitivity: LOD of 25 ng/ml
- Wide Dynamic Range: 0.1–25 μg/ml
- Precision: Intra- and Inter-assay %CV <10%
- Specificity: No cross-reactivity with related monoclonal antibodies
- Reliability: Analytical recovery of 80–120%
Applications in Clinical and Research Settings
The DeQuanto® kit is ideal for:
- Baseline Assessments: Establishing expected drug levels after initial doses.
- Non-Response Cases: Differentiating between pharmacokinetic and pharmacodynamic failure.
- Toxicity Management: Identifying unusually high drug levels in patients with adverse events.
- Special Populations: Monitoring patients with extreme body weights or organ dysfunction.
- Research Studies: Supporting clinical trials and pharmacokinetic research.
Technical Specifications
| Parameter | Specification |
|---|---|
| Product Category | Sandwich ELISA |
| Target Molecule | Free Nivolumab (OPDIVO) |
| Sample Type | Human plasma/serum |
| Calibration Range | 0.1–25 μg/ml |
| LOD | 25 ng/ml |
| Precision | Intra- and Inter-assay %CV <10% |
| Storage Temperature | -20°C (long-term), 2–8°C (shipping) |
| Regulatory Status | Research Use Only |
The Future of Personalized Immunotherapy
As cancer treatment moves toward personalized approaches, tools like the Nivolumab are essential. By integrating PK data with other biomarkers, clinicians can develop tailored treatment regimens that maximize efficacy and minimize risks.
Why Choose Denovo Biolabs?
As a trusted Make-in-India biotech company, Denovo is committed to delivering innovative solutions for cancer research and treatment. Our DeQuanto® Nivolumab PK ELISA Kit is rigorously validated, ensuring reliable performance for your clinical and research needs.
Contact Us
For more information about the Biosimilar or Research ELISA Kits reach out to us info@denovobiolabs.com.